InVitae Stock Price, News & Analysis (NYSE:NVTA)

$7.03 0.26 (3.84 %)
(As of 01/19/2018 01:52 PM ET)
Previous Close$6.77
Today's Range$6.64 - $7.19
52-Week Range$3.05 - $10.41
Volume1.44 million shs
Average Volume1.12 million shs
Market Capitalization$374.32 million
P/E Ratio-2.76
Dividend YieldN/A
BetaN/A

About InVitae (NYSE:NVTA)

InVitae logoInvitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Diagnostics & Testing
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:NVTA
CUSIPN/A
Phone+1-415-3747782

Debt

Debt-to-Equity Ratio0.33%
Current Ratio2.61%
Quick Ratio2.61%

Price-To-Earnings

Trailing P/E Ratio-2.75686274509804
Forward P/E Ratio-2.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.05 million
Price / Sales14.86
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.92

Profitability

Trailing EPS($2.55)
Net Income$-100,250,000.00
Net Margins-206.95%
Return on Equity-115.25%
Return on Assets-67.79%

Miscellaneous

Employees332
Outstanding Shares52,940,000

InVitae (NYSE:NVTA) Frequently Asked Questions

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) issued its earnings results on Monday, November, 6th. The medical research company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.02. InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%. View InVitae's Earnings History.

When will InVitae make its next earnings announcement?

InVitae is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for InVitae.

Where is InVitae's stock going? Where will InVitae's stock price be in 2018?

4 Wall Street analysts have issued 1 year price objectives for InVitae's stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate InVitae's stock price to reach $12.75 in the next twelve months. View Analyst Ratings for InVitae.

Who are some of InVitae's key competitors?

Who are InVitae's key executives?

InVitae's management team includes the folowing people:

  • Randal W. Scott Ph.D., Executive Chairman of the Board (Age 59)
  • Sean E. George Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 43)
  • Shelly D Guyer, Chief Financial Officer (Age 56)
  • Lee Bendekgey J.D., Chief Operating Officer, General Counsel, Secretary (Age 59)
  • Robert L. Nussbaum M.D., Chief Medical Officer (Age 67)
  • Christine M. Gorjanc, Lead Independent Director (Age 60)
  • Eric Aguiar M.D., Independent Director (Age 55)
  • Geoffrey S. Crouse, Independent Director (Age 46)

When did InVitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Who owns InVitae stock?

InVitae's stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.46%), Daiwa SB Investments Ltd. (0.12%) and Creative Planning (0.10%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Lisa Alderson, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George and Thomas Brida. View Institutional Ownership Trends for InVitae.

Who bought InVitae stock? Who is buying InVitae stock?

InVitae's stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Daiwa SB Investments Ltd. and Creative Planning. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse, Randal W Scott and Sean E George. View Insider Buying and Selling for InVitae.

How do I buy InVitae stock?

Shares of InVitae can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InVitae's stock price today?

One share of InVitae stock can currently be purchased for approximately $7.03.

How big of a company is InVitae?

InVitae has a market capitalization of $374.32 million and generates $25.05 million in revenue each year. The medical research company earns $-100,250,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. InVitae employs 332 workers across the globe.

How can I contact InVitae?

InVitae's mailing address is 1400 16th St, SAN FRANCISCO, CA 94103-5110, United States. The medical research company can be reached via phone at +1-415-3747782 or via email at [email protected]


MarketBeat Community Rating for InVitae (NVTA)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

InVitae (NYSE:NVTA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.75$14.33$14.33$14.00
Price Target Upside: 68.21% upside58.03% upside55.46% upside26.58% upside

InVitae (NYSE:NVTA) Consensus Price Target History

Price Target History for InVitae (NYSE:NVTA)

InVitae (NYSE:NVTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018BenchmarkLower Price TargetBuy -> Buy$16.00 -> $11.00MediumView Rating Details
1/16/2018Leerink SwannLower Price TargetOutperform -> Outperform$12.00 -> $10.00HighView Rating Details
1/5/2018Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$15.00HighView Rating Details
8/9/2017JPMorgan Chase & Co.Reiterated RatingOverweight$14.00 -> $15.00LowView Rating Details
(Data available from 1/19/2016 forward)

Earnings

InVitae (NYSE:NVTA) Earnings History and Estimates Chart

Earnings by Quarter for InVitae (NYSE:NVTA)

InVitae (NYSE NVTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.55)N/AView Earnings Details
11/6/2017Q3 2017($0.55)($0.57)ViewN/AView Earnings Details
8/7/20176/30/2017($0.64)($0.66)$13.31 million$14.34 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.68)($0.64)$10.90 million$10.34 millionViewListenView Earnings Details
2/13/2017Q416($0.73)($0.69)$8.82 million$9.20 millionViewN/AView Earnings Details
11/7/2016Q316($0.72)($0.77)$7.50 million$6.30 millionViewListenView Earnings Details
8/8/2016Q216($0.76)($0.77)$5.81 million$5.60 millionViewN/AView Earnings Details
5/9/2016Q116($0.76)($0.80)$4.38 million$4.00 millionViewN/AView Earnings Details
2/9/2016Q415($0.72)($0.76)$2.92 million$3.20 millionViewN/AView Earnings Details
11/5/2015Q315($0.70)($0.71)$2.55 million$2.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.55)($0.76)$1.67 million$1.80 millionViewN/AView Earnings Details
5/12/2015Q115($0.51)($1.09)$1.07 million$1.23 millionViewListenView Earnings Details
3/10/2015Q4 2014($16.75)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

InVitae (NYSE:NVTA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.90)
2019 EPS Consensus Estimate: ($1.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.56)($0.56)($0.56)
Q2 20181($0.49)($0.49)($0.49)
Q3 20181($0.46)($0.46)($0.46)
Q4 20181($0.39)($0.39)($0.39)
Q1 20191($0.41)($0.41)($0.41)
Q2 20191($0.38)($0.38)($0.38)
Q3 20191($0.33)($0.33)($0.33)
Q4 20191($0.21)($0.21)($0.21)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for InVitae (NYSE:NVTA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

InVitae (NYSE NVTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 64.67%
Insider Trades by Quarter for InVitae (NYSE:NVTA)
Institutional Ownership by Quarter for InVitae (NYSE:NVTA)

InVitae (NYSE NVTA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/10/2017Patty DumondVPSell2,497$10.00$24,970.00View SEC Filing  
10/9/2017Patty DumondVPSell1,882$10.00$18,820.0052,783View SEC Filing  
9/12/2017Katherine StuelandInsiderSell612$9.40$5,752.8058,570View SEC Filing  
2/16/2017Thomas BridaGeneral CounselSell766$9.69$7,422.5424,720View SEC Filing  
2/15/2017E Lee BendekgeyCFOSell2,098$9.59$20,119.8260,882View SEC Filing  
2/15/2017Patty DumondVPSell1,264$9.55$12,071.2055,929View SEC Filing  
2/15/2017Robert L NussbaumInsiderSell1,686$9.53$16,067.5862,823View SEC Filing  
2/15/2017Thomas BridaGeneral CounselSell794$9.54$7,574.7626,280View SEC Filing  
11/22/2016Randal W ScottChairmanBuy66,666$6.00$399,996.003,506,225View SEC Filing  
11/18/2016Geoffrey CrouseDirectorBuy15,000$6.25$93,750.0034,259View SEC Filing  
11/17/2016Bros. Advisors Lp BakerMajor ShareholderBuy733,333$6.00$4,399,998.00View SEC Filing  
9/16/2016Patty DumondVPSell1,000$8.00$8,000.009,812View SEC Filing  
8/15/2016Patty DumondVPSell1,000$8.81$8,810.009,812View SEC Filing  
7/14/2016Patty DumondVPSell1,000$8.79$8,790.009,812View SEC Filing  
6/16/2016Patty DumondVPSell1,000$8.00$8,000.009,812View SEC Filing  
5/17/2016Patty DumondVPSell3,221$8.47$27,281.8712,033View SEC Filing  
4/14/2016Patty DumondVPSell1,000$10.50$10,500.009,812View SEC Filing  
2/22/2016Lisa AldersonInsiderSell7,500$7.64$57,300.0031,819View SEC Filing  
2/11/2016Sean E GeorgeCOOBuy16,950$6.16$104,412.00235,408View SEC Filing  
2/18/2015James E FlynnInsiderBuy175,000$16.00$2,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

InVitae (NYSE NVTA) News Headlines

Source:
DateHeadline
Leerink Swann Equities Analysts Reduce Earnings Estimates for InVitae Corp (NVTA)Leerink Swann Equities Analysts Reduce Earnings Estimates for InVitae Corp (NVTA)
www.americanbankingnews.com - January 18 at 6:44 AM
InVitae Corp (NVTA) to Post Q1 2019 Earnings of ($0.41) Per Share, Leerink Swann ForecastsInVitae Corp (NVTA) to Post Q1 2019 Earnings of ($0.41) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 17 at 10:16 PM
InVitae (NVTA) Price Target Cut to $11.00InVitae (NVTA) Price Target Cut to $11.00
www.americanbankingnews.com - January 16 at 12:44 PM
InVitae (NVTA) Given New $10.00 Price Target at Leerink SwannInVitae (NVTA) Given New $10.00 Price Target at Leerink Swann
www.americanbankingnews.com - January 16 at 11:08 AM
Zacks: Brokerages Anticipate InVitae Corp (NVTA) Will Announce Earnings of -$0.57 Per ShareZacks: Brokerages Anticipate InVitae Corp (NVTA) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - January 12 at 11:32 AM
InVitae (NVTA) Reports Prelim. FY17 Slightly Below Consensus; Volume Exceeds Prior Guidance - StreetInsider.comInVitae (NVTA) Reports Prelim. FY17 Slightly Below Consensus; Volume Exceeds Prior Guidance - StreetInsider.com
www.streetinsider.com - January 8 at 4:40 PM
Here's Why Invitae Dropped as Much as 14.3% TodayHere's Why Invitae Dropped as Much as 14.3% Today
finance.yahoo.com - January 8 at 4:40 PM
Vermillion (VRML) and InVitae (NVTA) Head-To-Head ReviewVermillion (VRML) and InVitae (NVTA) Head-To-Head Review
www.americanbankingnews.com - January 6 at 5:12 PM
Ladenburg Thalmann Starts Invitae Corporation (NVTA) at Buy - StreetInsider.comLadenburg Thalmann Starts Invitae Corporation (NVTA) at Buy - StreetInsider.com
www.streetinsider.com - January 5 at 4:16 PM
InVitae Corp (NVTA) Receives Consensus Rating of "Hold" from BrokeragesInVitae Corp (NVTA) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 5 at 3:28 PM
InVitae (NVTA) Now Covered by Analysts at Ladenburg Thalmann Financial ServicesInVitae (NVTA) Now Covered by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 5 at 10:22 AM
InVitae (NVTA) Stock Rating Lowered by Zacks Investment ResearchInVitae (NVTA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 4 at 6:04 AM
ETFs with exposure to Invitae Corp. : January 2, 2018ETFs with exposure to Invitae Corp. : January 2, 2018
finance.yahoo.com - January 2 at 5:22 PM
Critical Review: InVitae (NVTA) vs. Vermillion (VRML)Critical Review: InVitae (NVTA) vs. Vermillion (VRML)
www.americanbankingnews.com - December 30 at 7:12 PM
InVitae Corp (NVTA) Expected to Announce Quarterly Sales of $25.87 MillionInVitae Corp (NVTA) Expected to Announce Quarterly Sales of $25.87 Million
www.americanbankingnews.com - December 28 at 4:28 AM
Zacks: Analysts Anticipate InVitae Corp (NVTA) Will Post Earnings of -$0.55 Per ShareZacks: Analysts Anticipate InVitae Corp (NVTA) Will Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 26 at 9:21 PM
-$0.55 EPS Expected for InVitae Corp (NVTA) This Quarter-$0.55 EPS Expected for InVitae Corp (NVTA) This Quarter
www.americanbankingnews.com - December 26 at 9:21 PM
ETFs with exposure to Invitae Corp. : December 22, 2017ETFs with exposure to Invitae Corp. : December 22, 2017
finance.yahoo.com - December 22 at 7:21 PM
ETFs with exposure to Invitae Corp. : December 11, 2017ETFs with exposure to Invitae Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:41 PM
Vermillion (VRML) & InVitae (NVTA) Critical ComparisonVermillion (VRML) & InVitae (NVTA) Critical Comparison
www.americanbankingnews.com - December 10 at 3:30 PM
InVitae Corp (NVTA) Expected to Announce Earnings of -$0.55 Per ShareInVitae Corp (NVTA) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 9 at 8:04 AM
Financial Survey: Veracyte (VCYT) versus InVitae (NVTA)Financial Survey: Veracyte (VCYT) versus InVitae (NVTA)
www.americanbankingnews.com - December 3 at 9:48 PM
Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 11:01 AM
Comparing Digiliti Money (DGLT) & InVitae (NVTA)Comparing Digiliti Money (DGLT) & InVitae (NVTA)
www.americanbankingnews.com - November 29 at 9:44 PM
Contrasting InVitae (NVTA) and CareDx (CDNA)Contrasting InVitae (NVTA) and CareDx (CDNA)
www.americanbankingnews.com - November 27 at 10:10 AM
Invitae Corporation (NVTA) Rating Lowered to Strong Sell at BidaskClubInvitae Corporation (NVTA) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - November 25 at 12:50 AM
$25.87 Million in Sales Expected for Invitae Corporation (NVTA) This Quarter$25.87 Million in Sales Expected for Invitae Corporation (NVTA) This Quarter
www.americanbankingnews.com - November 23 at 8:58 AM
Critical Analysis: CareDx (CDNA) and Invitae Corporation (NVTA)Critical Analysis: CareDx (CDNA) and Invitae Corporation (NVTA)
www.americanbankingnews.com - November 22 at 1:23 PM
-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter
www.americanbankingnews.com - November 21 at 9:24 AM
Lion Biotechnologies (IOVA) & Invitae Corporation (NVTA) Critical ReviewLion Biotechnologies (IOVA) & Invitae Corporation (NVTA) Critical Review
www.americanbankingnews.com - November 18 at 1:30 PM
Invitae Corporation (NVTA) Given Consensus Rating of "Hold" by BrokeragesInvitae Corporation (NVTA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 16 at 2:10 PM
Invitae reports 1Q lossInvitae reports 1Q loss
marketbeat.com - May 8 at 4:34 PM
Invitae Expands Test Menu for Proactive Genetic Testing in Healthy AdultsInvitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults
us.rd.yahoo.com - March 23 at 7:28 PM
Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics MeetingInvitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
us.rd.yahoo.com - March 22 at 9:10 AM
INVITAE CORP Files SEC form 10-K, Annual ReportINVITAE CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 7:40 PM
Get Ready: Biotech Is Ready To Break OutGet Ready: Biotech Is Ready To Break Out
seekingalpha.com - February 28 at 10:35 AM
18 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga18 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga
www.benzinga.com - February 14 at 10:12 PM
Q4 2016 Invitae Corp Earnings Release - Time Not SuppliedQ4 2016 Invitae Corp Earnings Release - Time Not Supplied
biz.yahoo.com - February 13 at 9:39 AM
Form 8-K Invitae Corp For: Jan 06 - StreetInsider.com - StreetInsider.comForm 8-K Invitae Corp For: Jan 06 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - January 13 at 12:37 AM
INVITAE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and ExINVITAE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex
biz.yahoo.com - January 9 at 7:38 PM
7:01 am Invitae acquires privately owned AltaVoice; financial details not disclosed7:01 am Invitae acquires privately owned AltaVoice; financial details not disclosed
us.rd.yahoo.com - January 7 at 5:42 AM
InVitae (NVTA) Says it Met Annual Volume Guidance, Sees Doubling in 2017 - StreetInsider.comInVitae (NVTA) Says it Met Annual Volume Guidance, Sees Doubling in 2017 - StreetInsider.com
www.streetinsider.com - January 6 at 7:39 PM
INVITAE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or DispositionINVITAE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition
biz.yahoo.com - January 6 at 7:39 PM
InVitae Execs Talk Genetics And Growth - BenzingaInVitae Execs Talk Genetics And Growth - Benzinga
www.benzinga.com - December 18 at 7:12 PM

SEC Filings

InVitae (NYSE:NVTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

InVitae (NYSE:NVTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

InVitae (NYSE NVTA) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.